GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage

Inclusion Criteria: * Confirmed diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage in conjunction with ICH by cranial computed tomography (CCT) or Magnetic Resonance Tomography (MRT) * Patients who need by judgement of a clinical neurologist or neurosurgeon surgical removal of the blood clot due to its space-occupying effects * Age greater or equal 18 years for men * Age greater or equal 18 years for women if confirmed infertility (e.g. hysterectomy or surgical sterilisation at least 3 months before study start) * For all other women age greater or equal 50 years with last menstrual bleeding at least one year before study start * Minimum hematoma diameter of 2 cm as measured in baseline CCT or MRT * Signed, written informed consent of patient or consent/assertion from the patient's legally acceptable representative/affiliated if the patient is unable to provide informed consent Exclusion Criteria: * Participation in any other clinical trial within the past 3 months or ongoing * Occurrence of inconsistency with initial diagnosis at baseline during surgery of the patient leading to unfulfilled inclusion criterion Hemorrhage secondary to tumour or trauma * Patients with a cerebellar hemorrhage or extension of a supratentorial hemorrhage into the brainstem * Patients with severe pre-existing physical or mental disability or severe comorbidity that interferes with the assessment of outcome * Allergy to contrast media (MRT) * Acute infection * Muscular, neurological, or vascular insufficiency of the respective tissue * Polypropylene incompatibility * Acute immunosuppressive medication * Patient after organ transplantation * Patient with immune depression * Patients with a high probability of spontaneous recovery or showing rapidly improving signs * Patients with extensive intracranial hemorrhages or with deep hemispheric localisation of the clots * Patients whose diagnosis of ICH is uncertain